Keywords: angiogenesis apoptosis inflammation interstitial cystitis painful bladder syndrome a b s t r a c t Objective: Protein arrays are rapidly becoming a powerful means to detect proteins, monitor their expression levels, and investigate protein interactions and functions. We used this technology and demonstrated its application in identifying potential biomarkers for the diagnosis and treatment of interstitial cystitis/painful bladder syndrome (IC/PBS).
Introduction
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a chronic, painful condition of the bladder wall characterized by pressure and pain above the pubic area along with increased frequency of urination and glomerulations in cystoscopic hydrodistention. In patients with IC/PBS, researchers have found specific pathologies, including abnormalities of the urothelium, changes in the nerve function within the bladder wall, and mast cell overactivation. 1, 2 This evidence suggests that several possible pathogenetic developmental pathways are involved in IC/PBS, including chronic inflammation. 3 Histologic studies of tissue biopsies of IC/ PBS patients have consistently reported signs of inflammation as evidenced by degranulation of mast cells and infiltration of mast cells, macrophages, and neutrophils. 4 One of the most common findings in IC/PBS patients is denudation or thinning of the bladder epithelium, suggesting altered regulation of urothelial homeostasis. 1 Our previous reports indicated that the terminal deoxynucleotidyl transferase nick end labeling (TUNEL)-positive cells were present in the bladder of IC/ PBS patients, and there was a significant positive correlation between mast cell activation and the apoptotic cell number in bladder tissues of patients with IC/PBS. 5 These results suggest that the urothelium plays a pivotal role as a barrier between the urine (and its solutes) and the underlying bladder tissues. During an inflammatory response, leukocytes must leave the vascular lumen and enter the tissue where they perform effecter functions. Signaling molecules and cytokines such as tumor necrosis factor (TNF) and interleukin (IL)-1 cause the expressions of intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 by neutrophils, which trigger vascular permeability abnormalities or physiologic angiogenesis. 6 The cardinal symptoms and signs of IC/PBS, such as bladder pain, increased bladder sensation, diffused glomerulations during hydrodistention, and reduced bladder capacity, all reflect the inflammatory process in the diseased bladder wall, and neural upregulation occurs both peripherally and centrally in the bladders of patients with IC/PBS. 7 The clinical presentations of IC/PBS are heterogeneous. 2 Patients with IC/PBS may have predominant bladder pain or predominant urgency frequency symptoms. Under cystoscopic hydrodistention, some patients may have a reduced maximum bladder capacity under anesthesia or mild to severe glomerulations or ulceration, but some do not show these features. 8 Although urine and serum biomarkers such as nerve growth factor (NGF), C-reactive protein (CRP), antiproliferative factor (APF), heparin-binding epidermal growth factorlike growth factor (HB-EGF), and epidermal growth factor (EGF) were found to be elevated in IC/PBS 1,9e11 not all IC/PBS bladders have elevated urinary biomarker levels, although they have typical bladder pain symptoms and cystoscopic findings. 3, 9, 10 Increased bladder mast cell activity 9 and proinflammatory and apoptotic protein expressions are also not consistently found in all IC/PBS bladder biopsies. 5, 12 Recent studies also revealed that the mast-cell density does not appear to correlate with the duration of symptom amelioration after complete transurethral resection of Hunner ulcer, 13 and overall urine markers were not associated with biopsy findings. 14 Therefore, we speculated that histologic findings, urinary biomarkers, and clinical presentations in IC/PBS might be heterogeneous.
In this study, we present the preliminary results of a proteomics analysis of the processes of inflammation, angiogenesis, and apoptosis in IC/PBS bladder tissues and urine samples, and focused on the crosstalk between different signaling pathways. Based on the proteomics findings in IC/PBS bladders, it is possible to link chronic inflammation, urothelial apoptosis, and angiogenesis in IC/ PBS. The results may facilitate future investigations and provide evidence for therapy targeting chronic inflammation in IC/PBS patients.
Patients and methods
Six women with characteristic symptoms of IC/PBS and diffuse glomerulations but no Hunner ulcer on cystoscopic hydrodistention were enrolled in this study. Another three women with stress urinary incontinence without bladder symptoms served as the controls. Bladder biopsies at three sites were taken immediately after cystoscopic hydrodistention for the diagnosis of IC/PBS and from normal controls during anti-incontinence procedures. No patient had previously been treated for IC/PBS before the bladder procedure. Urine samples were also obtained from one patient with Grade 2 glomerulations at the baseline who received three repeated intravesical onabotulinumtoxinA (BoNT-A) injections, and follow-up cystoscopic hydrodistention revealed completely resolution of the glomerulations.
This study was approved by the Institutional Review Board and Ethics Committee of Buddhist Tzu Chi General Hospital. Each patient was informed about the study rationale and procedures, and written informed consent to participate in the study was obtained before we began the bladder procedures.
The IC/PBS patients were classified by the degree of glomerulations after hydrodistention as Grades 0e3, respectively representing none, mild, moderate, and severe IC/PBS. 2 Specimens with Grade 2 and 3 (G2 or G3) for glomerulations without an ulcer were used in this study. The patients underwent three bladder biopsies at about 2 cm above the ureteral orifice on the lateral and posterior walls. Each specimen was 2 mm in diameter, and only bladder mucosa was obtained. The bladder biopsy specimens were sent to the pathology department for hematoxylin and eosin staining to exclude the possibility of carcinoma in situ. Specimens were also stored frozen in liquid nitrogen for further investigations. The bladder biopsies were taken at the same sites in the controls and were prepared using the same methods for comparison.
To compare the expression profiles of 30 proteins related to inflammation and 35 proteins related to apoptosis, we performed a protein array assay on the bladder tissues of normal and IC/PBS patients and identified several differentially expressed proteins using the Image J software (http://rsb.info.nih.gov/ij/index.html). 15 After the three BoNT-A injections, urine samples of the IC/PBS patient were analyzed for 20 angiogenesis proteins, and the results were compared with untreated baseline data.
Human apoptosis protein and cytokine antibody array
Extracted protein lysates (250 mg) of control and IC/PBS specimens were incubated on a human apoptosis protein array membrane (R&D Systems, Minneapolis, MN, USA) at 4 C overnight, washed three times for 5 minutes with a wash buffer, and then incubated with a horseradish peroxidase (HRP)-linked secondary antibody diluted 1:2000. After washing, blotted dots were visualized using a Western chemiluminescent HRP substrate (Millipore, Guyancourt, France). Normalized intensities were calculated from each array by subtracting the local background from each spot, and the data were corrected for the protein content in each well. Then multiples of change in protein expression levels between IC/PBS and control specimens were calculated.
The human cytokine antibody array procedure (RayBiotech, Norcross, GA, USA) was conducted according to the manufacturer's instructions. Briefly, membranes were blocked by incubation with blocking buffer at room temperature for 90 minutes. Membranes were washed three times with wash buffer I and two times with wash buffer II at room temperature for 5 minutes per wash, and incubated with biotin-conjugated antibodies at room temperature for 90 minutes. Finally, membranes were washed and incubated with HRP-conjugated streptavidin at room temperature for 2 hours. The chemiluminescent protein dot signals were measured as described above.
To investigate changes in angiogenesis proteins in IC/PBS bladders after three repeated BoNT-A injections, the urine of one IC/PBS patient was analyzed using an angiogenesis protein array, and the results were compared with the untreated baseline of the same patient. The patient exhibited improvement of glomerulations from Grade 2 to Grade 0 after BoNT-A treatment (Fig. 1A) . Two urine samples were used for the protein array, and 20 molecules for angiogenesis and vascular inflammation were investigated. The multiples of change in protein expression levels between the baseline and post-treatment in urine samples of IC/PBS patient were calculated. The results of the angiogenesis protein array from urine samples at the baseline and post-treatment might provide evidence of the effect of intravesical BoNT-A treatment.
Statistical analysis
The intensities of proteins in the arrays and Western blots were quantified using Image J processing. 15 Differences in expressions of inflammatory and apoptotic proteins between IC/PBS and control specimens were analyzed using the Kruskal-Wallis test. All calculations were performed using SPSS for Windows, version 10.0 (SPSS, Chicago, IL, USA). A p value of <0.05 was considered statistically significant.
Results

Inflammatory proteins
The inflammatory protein array comprised 30 spots of inflammation-related molecules spotted in duplicate, and positive Fig. 2). 
Apoptotic proteins
To better characterize molecular events leading to apoptosis in IC/PBS samples, we conducted an apoptosis-related protein-antibody array analysis of control and IC/PBS specimens. Results showed that 15 pro-or antiapoptotic proteins were significantly modulated (Fig. 3) . Among proapoptotic proteins known to mediate the apoptotic process, levels of Bax, TRAIL R2, FADD, Fas, and phosphop53 increased. Strikingly, some antiapoptotic proteins, such as Bcl-2, members of the heat shock proteins (HSPs), cyclin-dependent kinase (CDK) inhibitor, p21, and p27, also significantly increased.
Angiogenesis proteins
After BoNT-A treatment, the urine of the IC/PBS patient was analyzed using an angiogenesis protein array, and results were compared with the untreated baseline of the same patient. As shown in Fig. 1B , 92% of molecules related to angiogenesis and vascular inflammation on the array membrane were suppressed. Fig. 1C shows that protein expressions dramatically decreased after the BoNT-A injections, such as vascular endothelial growth factor (VEGF), platelet factor 4, IL-1b, IL-8, chemokine (C-X-C motif) ligand 16, and TIMP-4.
Discussion
This was a pilot study investigating protein expression profiles of inflammation, urothelial apoptosis, and angiogenesis in IC/PBS patients using a protein array technique. Further confirmative studies are mandatory in order to explore the heterogeneity of IC/ PBS and mechanisms of therapeutic effects of varying treatment modalities for IC/PBS.
Previous studies demonstrated that IC/PBS patients have altered bladder epithelial expressions of HLA-DR and ICAM-a, and secreted proteins, including IL-1, TNF-a, and various epithelial growth factors such as HB-EGF, EGF, and IGF1.
16e19 Studies on urothelial dysfunction in IC/PBS also showed altered expressions of certain tight junction proteins such as zona occludens-1, occluding, and claudins 1, 4, and 8. 20, 21 Urine samples from IC/PBS patients also showed significantly decreased HB-EGF and increased levels of EGF, IGF1, IGFBP3, and cytokines, including IL-6 and IL-8. 22 Those findings indicate that several inflammatory processes are involved in IC/PBS and are responsible for the clinical symptoms and signs. Basic research has demonstrated that cardinal signs of inflammation such as infiltration of mononuclear cells, activation of mast cells, and neovascularization (angiogenesis) are orchestrated by chemokines, cytokines, and growth factors in IC/PBS bladders. 23, 24 During the development of inflammation, two major events occur. Leukocytes interact with the endothelium in a process that allows these cells to cross the barrier created by endothelial cells. This cellular migration results in modifications of the vascular permeability that permits the transfer of solutes to peripheral tissues. Under basal conditions, alterations in vascular permeability are linked to ICAM-1 expression in a protein kinase C (PKC)-dependent manner. 25 Matrix metalloproteinases (MMPs) can degrade components of the extracellular matrix (ECM). Activities of MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMPs) through formation of non-covalent 1:1 complexes with MMPs. Four members of the TIMP family have been characterized so far, designated TIMP-1, -2, -3, and -4. TIMP-1 is capable of inhibiting the activities of most MMPs, and plays a key role in maintaining the balance between ECM deposition and degradation as several inflammatory mediators are substrates of MMPs. TIMP-1 might affect renal fibrosis via an inflammatory pathway. 26 A multitude of vasoactive cytokines, growth factors, and signal modulators react with endothelial cell substructure components to control permeability. VEGF, IL-a and -b, TNF-a, and interferon (IFN)-g were shown to increase endothelial monolayer permeability. 27 Lipopolysaccharide (LPS) induces junction barrier loss and cell detachment by activating PTKs and caspase cleavage reactions. 28 By contrast, junctional adhesion molecules (JAMs) decrease permeability by initiating cell adhesion. Endothelial cell adhesive characteristics provide strength and stability for neighboring cells and the cellular cytoskeleton by interacting with actin and myosin contractile filaments. 29 Thrombin stimulation of cytoskeletal signaling pathways was shown to manipulate cell permeability. Junctional molecules also influence cell signaling and trigger responses that are translated into cell morphological changes and physiological angiogenesis. 30 Incubation of human aortic endothelial cells (HAECs) with IL-1a resulted in increased permeability of quercetin-3-glucuronide. Furthermore, quercetin-3-glucuronide showed no suppressive effect on TNF-a-induced cell expression of ICAM-1 by HAECs. MIP-1a is a member of the C-C subfamily of chemokines, a large superfamily of low-molecular-weight, inducible proteins that exhibit a variety of proinflammatory activities in vitro, including leukocyte chemotaxis. 31 Among apoptotic and inflammatory proteins, Bad, Bax, caspase 3, p53, p27, and TNF-a were confirmed by Western blot and statistical analyses to have higher expression levels in IC/PBS bladders than in normal bladders. 12 In this pilot study, changes in Bad and caspase 3 did not reach statistical significance, possibly due to the small sample size. Previous research also indicated that phosphorylation of p53 by p38a can play a role in p53-dependent transcription. 32 In addition, p53 is translocated into mitochondria to interact with Bcl-2 or Bcl-xl, thereby activating Bax directly or indirectly, and leading to caspase-dependent apoptosis. Previously, evidence showed that the extranuclear role of p53 in inducing apoptosis is through mechanisms involving Bad and Bax, which are the main factors that mediate mitochondrial dysfunction and cell apoptosis. 33 Additionally, p53 also participates in cell cycle arrest through inducing p21 and p27 activities. These proteins are potential biomarkers for diagnosing IC/PBS. Our findings indicate that apoptosis and growth arrest of bladder tissues of IC/PBS patients could be due to upregulation of inflammatory signals.
In addition, TNF-a also promotes apoptosis through binding to TNF-receptor 1, resulting in many effects ranging from inflammation to apoptosis. 34 TNF-a is a pleiotropic molecule that plays a central role in inflammation, apoptosis, and immune system development. 35 Previously, the nature of neurogenic pain was studied in animal models, and these pain models indicated that cytokines (TNF-a and NGF) were upregulated in injured nerves, and neutralizing TNF-a reduced pain behavior. 36, 37 More exactly, the primary role of TNF-a is in regulating immune cells, and it can also induce apoptotic cell death through activation of the transcription factors, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and c-Jun N-terminal kinase. 38 Taken together, our protein array results revealed that several inflammatory proteins were significantly increased in bladder tissues of IC/BPS patients, and several proapoptotic and antiapoptotic proteins increased. The urine angiogenesis array also showed decreases in angiogenesis and inflammatory proteins after The significance of changes in protein expression levels between the control and IC/PBS samples was determined using the Kruskal-Wallis test. *p < 0.05. **p < 0.005. ***p < 0.001. three repeated intravesical BoNTA injections. These protein expression profiles of inflammation, apoptosis, and angiogenesis suggest a network might exist in the IC/PBS bladder and could explain the pathophysiology of the clinical features of IC/PBS. Although this is a small pilot study, the results can provide valuable evidence for future investigations of heterogeneous pathogenesis and therapeutic effects of treatments for IC/PBS.
The limitation of this study is the small sample number (six IC/ PBS patients and three controls), and only the bladder mucosa was harvested. However, because this is a pilot study for the protein profile study of IC/PBS patients, results of this study can help us select appropriate proteins for further large-scale investigations of the pathophysiology and treatment results of IC/PBS.
Conclusions
In this study, we describe the first findings obtained by proteomic studies of the molecular mechanisms of IC/PBS, including correlations among inflammation, angiogenesis, and apoptosis. To further confirm the information obtained from the protein array, advanced analytical techniques such immunoblotting and enzymelinked immunosorbent assay are required. We provide a powerful research protocol for understanding the pathology of IC/PBS, and even other urologic diseases.
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